Introduction
Staphylococci are a major cause of nosocomial infections. In a multicentre European study, staphylococci accounted for 49% of infections in intensive care units. 1 Increasing numbers of these are methicillin-resistant Staphylococcus aureus (MRSA). In a multicentre study of the Paul Ehrlich Society in Germany, Austria and Switzerland, the incidence of MRSA in relation to all S. aureus was 13% during 1995. The same group found an increase in resistance of S. aureus to fluoroquinolones in Central Europe from 0% to 12.8% during the past 15 years. 2 At the present time, glycopeptides are the only available antibiotics for the empirical treatment of infections due to MRSA resistant to quinolones.
Moxifloxacin (BAY 12-8039) is a new 8-methoxyquinolone with improved activity against Gram-positive cocci in comparison with ofloxacin and ciprofloxacin. It is active against Streptococcus pneumoniae, Streptococcus pyogenes and Streptococcus agalactiae irrespective of their susceptibility to ciprofloxacin. Its activity against Gramnegative bacteria is similar to that of ciprofloxacin, except for Pseudomonas aeruginosa. 3, 4 Against methicillin-susceptible S. aureus, MICs 0.1 mg/L of moxifloxacin and 1 mg/L for ciprofloxacin are reported. The new fluoroquinolone was still active (MIC 8 mg/L) against ciprofloxacin-resistant MRSA (MIC 32 mg/L). 5 Quinolones accumulate in phagocytic cells and are bactericidal against intracellular bacteria. 6, 7 We studied the activity of moxifloxacin in comparison with that of ciprofloxacin against S. aureus susceptible and resistant to oxacillin and ciprofloxacin in the presence of human phagocytes (PMN).
Materials and methods

Bacteria
Eight S. aureus were studied: two quality control (QC) strains (S. aureus ATCC 25923 and NCTC 6571), three MRSA: (resistant to oxacillin, sensitive to ciprofloxacin) 
Antibiotics and media
Ciprofloxacin and Bay 12-8036 were prepared freshly for each experiment. All tests were performed in Medium 199 (no. F0615; Merck, Darmstadt, Germany) containing 5% fetal calf serum (no. 50113; Biochrom, Berlin, Germany). MICs were determined in Meuller-Hinton broth.
Polymorphonuclear leucocytes
PMN were harvested from fresh blood of healthy, male volunteers less than 30 years of age. PMN were enriched by differential centrifugation on a Percoll density-gradient. Viability was checked by staining with trypan blue and the number of cells was determined in a Neubauer chamber and adjusted to a concentration of 10 7 cells/mL. All experiments were repeated with PMN from at least three different donors.
Phagocytosis assay
PMN and opsonized bacteria were incubated at a ratio of 1:10 for 15 min at 37 C. Extracellular bacteria were removed by differential centrifugation as described previously.
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Intracellular activity
Phagocytosed bacteria were divided into four aliquots with different concentrations of the drug (0, 0.1, 1 and 10 MIC). At baseline and after 1, 2 and 4 h incubation, the number of viable bacteria was determined by a subculture technique. PMN were lysed by hypotonic shock.
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Results
Ciprofloxacin and moxifloxacin were both active against QC strains and MRSA, with MICs of 0.5 mg/L and 0.063 mg/L, respectively. Against M-Cip-RSA, the MIC of ciprofloxacin was 16 mg/L with a median of 32 mg/L. M-Cip-RSA remained sensitive to moxifloxacin at concentrations of 2 mg/L.
Quality control strains
At 0.1 MIC, both drugs showed only a weak bacteriostatic effect against extracellular and intracellular staphylococci (data not shown). A similar effect was seen at 1 MIC. At 10 MIC, moxifloxacin had only weak intracellular and extracellular activity, whereas ciprofloxacin was highly bactericidal, killing 99% of extracellular and 80% of intracellular staphylococci after 4 h. However, it should be noted that, because of the higher MIC of ciprofloxacin, the concentrations leading to this activity were nearly 10 times higher than those of moxifloxacin.
Methicillin-resistant isolates
The activities of the two quinolones against MRSA susceptible to ciprofloxacin are shown in Figure 1 . Neither ciprofloxacin nor moxifloxacin was bactericidal at 0.1 or 1 MIC (data not shown). At 10 MIC, both antibiotics killed approximately 90% of the extracellular and intracellular bacteria after 4 h.
Methicillin-and ciprofloxacin-resistant isolates
As shown in Figure 2 , intra-and extracellular growth of staphylococci was not reduced at 0.1 MIC. At 1 MIC, only a bacteriostatic effect was observed (data not shown). At concentrations of 10 MIC, moxifloxacin killed 95% of the extracellular M-Cip-RSA and 50% of the intracellular M-Cip-RSA after 4 h. Ciprofloxacin did not show bactericidal activity against ingested and non-ingested M-Cip-RSA.
Discussion
Moxifloxacin was active against all tested staphylococci with MICs of 0.063-2 mg/L. The MICs of ciprofloxacin against the tested strains were nearly ten times higher, reaching values up to 32 mg/L. Lower MICs of moxifloxacin have been reported against MRSA. 7 Both drugs showed only a weak bacteriostatic effect at 0.1 and 1 MIC. Moxifloxacin achieves this activity at nearly ten times lower concentrations than ciprofloxacin. At concentrations of 10 MIC, both drugs inhibited the growth of intracellular and extracellular staphylococci. Ciprofloxacin was more bactericidal against QC strains than moxifloxacin, albeit at higher concentrations.
After oral administration of 400, 600 and 800 mg of moxifloxacin, serum levels of 3.36, 4.21 and 4.73 mg/L, respectively are reported, 10 suggesting than moxifloxacin could be an alternative to glycopeptides for the treatment of infections caused by MRSA. In future, intracellular concentrations of moxifloxacin should be evaluated. 
